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Supplementary	  Figure	  1.	  Study	  design.	  Design	  of	  CHARGE	  consor�um	  discovery	  of	  novel	  
variants	  associated	  with	  fas�ng	  glucose	  (FG)	  and	  fas�ng	  insulin	  (FI),	  and	  the	  type	  of	  follow-­‐up	  
performed	  on	  novel	  and	  known	  loci.	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Supplementary	  Figure	  2.	  Detailed	  Comparison	  of	  A316	  (WT)	  with	  T316	  (mutant).	  The	  ﬁgure	  
shows	  that	  in	  the	  wildtype	  (WT)	  receptor	  (A316),	  residue	  N320	  (transmembrane	  (TM)	  5)	  is	  
involved	  in	  a	  hydrogen-­‐bonding	  interac�on	  with	  E364	  (TM6),	  whereas	  in	  the	  mutant	  receptor	  
the	  T316	  residue	  displaces	  N320	  and	  takes	  its	  place	  to	  engage	  in	  a	  stable	  interac�on	  with	  E364.	  
These	  changes	  then	  aﬀect	  the	  posi�ons	  of	  TM5	  and	  TM6,	  as	  well	  as	  the	  conforma�on	  of	  the	  
intracellular	  loop	  3	  (that	  connects	  TM5	  and	  TM6	  inside	  the	  cell).	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Supplementary	  Figure	  3.	  Eﬀect	  of	  mutant	  GLP-­‐1	  receptor	  on	  posi�on	  in	  the	  cell	  membrane.	  
This	  ﬁgure	  displays	  the	  receptor	  mutant	  embedded	  in	  the	  membrane	  with	  the	  receptor	  color	  
capturing	  the	  ﬂuctua�ons	  and	  devia�ons	  (red	  for	  less	  and	  green/blue	  for	  more)	  in	  the	  mutant	  
compared	  to	  the	  wild	  type	  (WT)	  receptor.	  Transmembrane	  domain	  5	  (TM5),	  which	  contains	  
A316T,	  and	  TM1	  show	  the	  largest	  changes	  in	  conforma�on/posi�on.	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Supplementary	  Figure	  4.	  Global	  changes	  in	  the	  transmembrane	  domains	  of	  the	  mutant	  GLP1R	  
and	  exendin-­‐4	  (EXE4)	  system.	  This	  ﬁgure	  compares	  the	  global	  changes	  in	  the	  transmembrane	  
(TM)	  domains	  for	  the	  A316	  (WT)	  receptor	  and	  EXE4	  (in	  blue	  and	  purple,	  respec�vely)	  versus	  the	  
T316	  (mutant)	  receptor	  and	  EXE4	  (in	  orange	  and	  cyan,	  respec�vely),	  showing	  that	  TM5	  shi�s	  
slightly	  down	  towards	  the	  cytoplasm	  and	  TM6	  shi�s	  slightly	  upward.	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Supplementary	  Figure	  5.	  Associa�on	  signals,	  linkage	  disequilibrium,	  
transcrip�onal	  and	  epigene�c	  landscapes	  of	  signiﬁcant	  SNVs	  at	  the	  ABO	  locus	  	  
(a)	  Regional	  associa�on	  results	  (-­‐log10p)	  for	  fas�ng	  glucose	  of	  the	  ABO	  locus	  and	  within	  
500KB	  around	  the	  lead	  SNV	  (rs651007,	  purple	  dot);	  rs579459,	  rs653634	  and	  rs507666	  are	  
also	  shown	  and	  are	  in	  strong	  linkage	  disequilibrium	  (LD)	  with	  rs651007	  (r2=0.95-­‐1).	  	  r2	  
indicated	  by	  color	  scale	  legend.	  	  Triangle	  symbols	  indicate	  variants	  with	  MAF>5%,	  square	  
symbols	  indicate	  variants	  with	  MAF1-­‐5%,	  and	  circle	  symbols	  indicate	  variants	  with	  MAF	  
<1%.	  
(b)	  Inset	  of	  ABO	  gene	  with	  lead	  SNVs	  from	  FG	  analysis	  (labeled	  “FG	  associated”)	  depic�ng	  
low	  LD	  (r2)	  with	  the	  major	  blood	  group	  variants	  (labeled	  “Blood	  Type”)	  in	  European	  (CEU,	  
top)	  and	  African	  (YRI,	  bo�om)	  individuals.	  	  Major	  blood	  group	  variants	  were	  not	  genotyped	  
on	  the	  exome	  chip;	  therefore	  r2	  was	  calculated	  from	  the	  1000	  Genomes	  project	  (Phase	  1,	  
version	  3).	  
(c)	  An	  expressed	  sequence	  tag	  (EST)-­‐supported	  an�sense	  transcript	  from	  islets	  overlaps	  
ABO	  exon	  1.	  	  RED	  arrow:	  Genomic	  span	  of	  the	  ABO	  gene.	  The	  panel	  highlighted	  (light	  green,	  
below)	  is	  the	  UCSC	  Expressed	  Sequence	  Tags	  (EST)	  Track.	  BLUE	  arrow:	  Genomic	  span	  of	  the	  
EST-­‐supported	  an�sense	  transcript.	  BLUE	  Ellipse:	  ESTs	  suppor�ng	  an�sense	  transcrip�on.	  
(d)	  Inset	  of	  the	  ABO	  upstream	  region,	  promoter,5’	  untranslated	  region	  (5’UTR)	  and	  part	  of	  
intron	  1.	  The	  intronic	  SNV	  rs507666	  is	  near	  the	  transcrip�on	  start	  site	  of	  the	  expressed	  
sequence	  tag	  (EST)	  CK821046	  from	  a	  human	  islet	  cDNA	  library.	  Two	  other	  ESTs,	  also	  from	  
human	  islets,	  support	  this	  an�sense	  non-­‐coding	  transcript.	  This	  EST	  is	  an�sense	  to	  exon	  1	  
of	  ABO,	  sugges�ng	  that	  rs507666	  may	  func�on	  as	  a	  promoter	  SNV	  of	  a	  previously	  
uncharacterized	  ABO	  an�sense	  non-­‐coding	  RNA	  transcript	  in	  islet	  cells.	  The	  intergenic	  SNVs	  
rs651007	  and	  rs579459	  reside	  in	  a	  DNAsel	  hypersensi�ve	  site	  cluster,	  overlapping	  an	  
H3K27Ac	  peak	  and	  par�ally	  overlapping	  a	  transcrip�on	  factor	  binding	  site	  (TFBS)	  ChIP-­‐seq	  
peak	  upstream	  of	  the	  ABO	  promoter.	  The	  sequences	  encompassing	  these	  SNVs	  may,	  
therefore,	  represent	  puta�ve	  ac�ve	  chroma�n	  regulatory	  elements	  whose	  func�on	  may	  be	  
altered	  by	  these	  SNVs.	  The	  intergenic	  SNV	  rs635634	  had	  less	  evidence	  for	  transcrip�onal	  or	  
regulatory	  ac�vity.	  Purple	  Boxes:	  Two	  variants	  (rs507666,	  rs635634)	  were	  annotated	  as	  
eQTLs	  for	  SLC2A6	  (gene	  to	  the	  right	  of	  ABO	  in	  panel	  A)	  from	  GTEx	  analysis.	  	  Blue	  Box:	  The	  
ENCODE	  H3K4Me1	  (enhancer),	  H3K27Ac	  (ac�ve	  regulatory	  element),	  DNAse	  I	  
hypersensi�ve	  sites,	  and	  TFBS	  ChIP-­‐Seq	  tracks,	  all	  with	  signals	  overlapping	  the	  SNVs,	  are	  
shown.	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Supplementary	  Figure	  6.	  ENCODE	  enrichment	  analyses.	  	  Overlap	  of	  
ABO	  locus	  SNP	  LD	  block	  with	  ENCODE	  func�onal	  marks.	  Each	  plot	  
shows	  the	  distribu�on	  of	  all	  SNPs	  or	  SNP	  LD	  blocks	  (ABO	  SNP	  LD	  block	  
of	  interest	  is	  the	  larger	  red	  point;	  smaller	  red	  points	  are	  GWAS	  SNPs;	  
blue	  points	  are	  non-­‐GWAS	  SNPs).	  Each	  point	  represents	  a	  single	  SNP	  or	  
SNP	  LD	  block	  and	  its	  loca�on	  represents	  the	  SNPs	  overlap	  (score	  of	  
each	  mark	  overlapped	  or	  sum	  for	  marks	  with	  mul�ple	  types;	  i.e.	  TFBS)	  
with	  the	  ENCODE	  func�onal	  mark	  denoted.	  Scores	  are	  averaged	  over	  
LD	  blocks.	  Each	  plot	  is	  shown	  in	  raw	  and	  log10	  scale.	  Contour	  lines	  are	  
created	  with	  the	  R	  func�on	  kde2d	  in	  order	  to	  represent	  the	  density	  of	  
all	  points	  in	  each	  plot.	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Supplementary	  Figure	  6	  (con�nued).	  ENCODE	  enrichment	  analyses.	  	  
Overlap	  of	  ABO	  locus	  SNP	  LD	  block	  with	  ENCODE	  func�onal	  marks.	  Each	  
plot	  shows	  the	  distribu�on	  of	  all	  SNPs	  or	  SNP	  LD	  blocks	  (ABO	  SNP	  LD	  
block	  of	  interest	  is	  the	  larger	  red	  point;	  smaller	  red	  points	  are	  GWAS	  
SNPs;	  blue	  points	  are	  non-­‐GWAS	  SNPs).	  Each	  point	  represents	  a	  single	  
SNP	  or	  SNP	  LD	  block	  and	  its	  loca�on	  represents	  the	  SNPs	  overlap	  (score	  
of	  each	  mark	  overlapped	  or	  sum	  for	  marks	  with	  mul�ple	  types;	  i.e.	  
TFBS)	  with	  the	  ENCODE	  func�onal	  mark	  denoted.	  Scores	  are	  averaged	  
over	  LD	  blocks.	  Each	  plot	  is	  shown	  in	  raw	  and	  log10	  scale.	  Contour	  lines	  
are	  created	  with	  the	  R	  func�on	  kde2d	  in	  order	  to	  represent	  the	  density	  
of	  all	  points	  in	  each	  plot.	  
a.	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Supplementary	  Figure	  7.	  The	  rela�onship	  of	  the	  common	  intronic	  variant	  rs560887	  to	  
epigene�c	  marks,	  transcrip�onal	  regula�on,	  and	  splicing	  at	  the	  G6PC2	  locus	  	  
(a)	  Figure	  of	  G6PC2	  gene	  structure	  showing	  the	  loca�on	  of	  rs560887	  and	  nearby	  ENCODE	  
epigene�c	  signatures.	  
(b)	  Zoomed-­‐in	  plot	  showing	  the	  EST	  DB031634	  and	  the	  splice	  site	  of	  G6PC2	  nearest	  to	  rs560887.	  
The	  intronic	  SNV	  rs560887	  was	  assessed	  as	  signiﬁcant	  in	  11	  independent	  NHGRI-­‐catalogued	  
GWAS	  studies	  (green,	  top,	  A)	  of	  serum	  metabolites,	  pregnancy-­‐associated	  glycemia,	  fas�ng	  
glucose	  levels,	  atherosclerosis,	  and	  body	  mass	  index	  (h�p://genome.ucsc.edu/cgi-­‐bin/hgc?
hgsid=369635347_bV0VuuwNQelM7MRwqH5tEyMLIvjx&c=chr2&o=169763147&t=169763148&
g=gwasCatalog&i=rs560887).	  The	  SNV	  resides	  at	  the	  5’end	  of	  an	  ENCODE	  H3K4Me1	  (puta�ve	  
enhancer)	  signature,	  sugges�ng	  that	  it	  may	  have	  a	  regulatory	  role	  (Layered	  H3K4Me1,	  middle,	  
A).	  There	  are	  several	  ENCODE	  transcrip�on	  factor	  binding	  sites	  evident	  in	  ChIP-­‐seq	  data	  in	  the	  
last	  exon	  of	  G6PC2	  (bo�om,	  a),	  further	  sugges�ng	  that	  the	  region	  may	  have	  regulatory	  func�ons	  
impac�ng	  the	  expression	  of	  G6PC2	  or	  other	  genes.	  The	  intronic	  SNV	  rs560887	  is	  also	  exonic	  with	  
respect	  to	  the	  EST	  DB031634,	  a	  posi�ve-­‐strand	  (same	  as	  G6PC2)	  transcript	  that	  may	  represent	  a	  
cryp�c	  minor	  isoform	  of	  G6PC2	  ini�a�ng	  from	  an	  internal	  promoter	  in	  the	  intron	  where	  this	  SNV	  
resides	  (b).	  This	  SNV	  is	  25	  bases	  upstream	  of	  the	  intron’s	  splice	  acceptor	  (b),	  sugges�ng	  that	  it	  
may	  also	  func�on	  as	  a	  regulator	  of	  G6PC2	  splicing.	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Supplementary	  Figure	  8:	  	  Regional	  associa�on	  plots	  for	  known	  
fas�ng	  glucose	  and	  fas�ng	  insulin	  loci	  and	  including	  only	  
nonsynonymous,	  splice	  or	  stop-­‐gain/loss	  variants	  	  
Regional	  associa�on	  results	  (-­‐log10p)	  for	  fas�ng	  glucose	  (FG)	  (a-­‐f)	  and	  
fas�ng	  insulin	  (FI)	  (g).	  
(a)	  DNLZ-­‐GPSM1	  
(b)	  SLC30A8	  
(c)	  SLC2A2	  
(d)	  RREB1:	  footnote,	  rs675209	  is	  the	  highest	  quality	  (but	  a	  poor)	  
proxy	  for	  the	  index	  GWAS	  FG	  SNV	  (rs17762454;	  r2=0.46,	  D’=0.71)	  
available	  on	  the	  Exome	  chip.	  
(e)	  MADD-­‐ACP2	  
(f)	  IKBKAP-­‐FAM206A	  
(g)	  GRB14-­‐COBLL1	  
Supplementary	  Figure	  9.	  Cluster	  plots	  of	  the	  newly	  reported	  variants	  from	  CHARGE	  joint	  
calling.	  	  
(a)  rs10305492	  –	  GLP1R	  (A316T)	  	  
(b)	  rs651007	  –	  ABO	  
a.	  	  rs10305492	  –	  GLP1R	   b.	  	  rs651007	  –	  ABO	  
Supplementary	  Figure	  10.	  Quan�le-­‐quan�le	  (QQ)	  plots	  from	  single	  variant	  associa�on	  meta-­‐
analysis	  of	  (a)	  fas�ng	  glucose,	  (b)	  fas�ng	  insulin	  and	  (c)	  type	  2	  diabetes	  associa�ons	  without	  
known	  variants	  
a.	  
b.	  
c.	  
	  Supplementary Tables 
 
Supplementary Table 1. Association of novel fasting glucose loci with fasting insulin 
 
Gene rsID Chr Build 37 position Variation type 
Alleles 
EAF Beta SE p N 
Effect Other 
GLP1R rs10305492 6 39046794 nonsynonymous A G 0.015 0.005 0.011 0.67 47388 
ABO rs507666 9 136149399 intronic A G 0.177 0.007 0.004 0.05 47388 
ABO rs651007 9 136153875 intergenic A G 0.201 0.008 0.003 0.02 47148 
ABO rs579459 9 136154168 intergenic C T 0.201 0.008 0.003 0.02 47148 
ABO rs635634 9 136155000 intergenic A G 0.177 0.008 0.004 0.03 47148 
Fasting insulin concentrations were log transformed and adjusted for sex, age, BMI, cohort effects and up to 10 principal 
components in up to 48,118 non-diabetic individuals.  Effects are reported per copy of the minor allele.  EAF: Effect allele 
frequency; N: sample size 
 
	  Supplementary Table 2. Sample sizes from cohorts participating in the glycemic physiologic trait analyses 
	  
  Sample sizes for traits derived from oral glucose tolerance test (OGTT) 
paired IVGTT 
and OGTT Cohorts 2h-glucose 2h-insulin 30min insulin insulinogenic index AUC insulin 
ratio of AUC 
ins/ AUC gluc 
Ely 1392 1377 1361 1345 1303 1217 NA 
Fenland 6319 NA NA NA NA NA NA 
CoLaus 498 NA NA NA NA NA NA 
FHS 5716 2625 NA NA NA NA NA 
ARIC 6707 NA NA NA NA NA NA 
GLACIER 916 NA NA NA NA NA NA 
Health2008 608 611 594 573 593 589 NA 
Inter99 5419 5268 5210 4979 4872 4854 NA 
METSIM 8230 8221 8189 8113 8182 8181 NA 
RISC 1275 1260 1247 1193 1176 1174 738 
        
total N 37080 19362 16601 16203 16126 16015 738 
Glycemic physiologic traits were tested for association with GLP1R A316T rs10305492. See methods for estimation of glycemic trait 
measurements. 
	  Supplementary Table 3. Association of GLP1R A316T and insulin sensitivity 
 
SI from frequently sampled IV glucose 
tolerance test* 
Standardized M/I from clamp 
IRAS study 
(n=184)** 
IRAS Family study 
(n=1,024)*** 
RISC & ULSAM studies 
(n=2,170) 
Beta (SE) 
p 
Beta (SE) 
p 
Beta (SD) p 
0.51 (0.3) 0.13 -0.23 (0.2) 0.11 -0.04 (-0.25, 0.17) 0.71 
Results are presented per minor allele. *Log transformed. **African-
Americans. ***Hispanic-Americans 
	  Supplementary Table 4. Genes included in the GLP1R pathway for MAGENTA 
gene-set enrichment analysis	  
 
Gene 
ADCY1 ADCY5 ADCY9 CALM2 GCG GLP2R PCLO PRKX VIP 
ADCY2 ADCY6 ADCYAP1 CALM3 GIP GNAS PDX1 RAB3A VIPR1 
ADCY3 ADCY7 ADCYAP1R1 CREB1 GIPR ITPR3 PRKACA RAPGEF3 VIPR2 
ADCY4 ADCY8 CALM1 DPP4 GLP1R MZB1 PRKACB RIMS2 WFS1 
Set of 36 genes were defined as having putative biological functions in a pathway between 
GLP1R activation and insulin secretion. 
	  Supplementary Table 5. Annotation descriptions of exome sequence SNVs for 
GLP1R and G6PC2 in all SNVs and stratified by MAF<1% and MAF≥1%	  
 
Variation type 
GLP1R G6PC2 
All MAF MAF<1% MAF≥1% All MAF MAF<1% MAF≥1% 
Nonsynonymous 34 30 4 33 30 3 
Splicing 0 0 0 1 1 0 
Stopgain 2 2 0 4 4 0 
Synonymous 29 24 5 9 9 0 
Intronic 81 61 20 19 16 3 
3' UTR 3 3 0 2 1 1 
5' UTR 1 1 0 0 0 0 
       
TOTAL 150 121 29 68 61 7 
MAF: minor allele frequency; UTR: untranslated region 	   	   	  
	  Supplementary Table 6. Novel ABO SNPs associated with fasting glucose in African and European ancestries 
combined and stratified by ancestry 
 
rsID 
Alleles	   Combined ancestry analysis European ancestry analysis African ancestry analysis 
Effect Other EAF Beta SE p pconda EAF Beta SE p pconda EAF Beta SE p pconda 
rs507666 A G 0.17 0.02 0.004 7.4E-08 0.28 0.19 0.02 0.004 4.0E-07 0.60 0.10 0.03 0.015 0.02 0.11 
rs651007 A G 0.20 0.02 0.004 1.3E-08 NA 0.21 0.02 0.004 5.8E-08 NA 0.14 0.02 0.013 0.09 NA 
rs579459 C T 0.20 0.02 0.004 2.6E-08 0.15 0.21 0.02 0.004 6.5E-08 0.25 0.14 0.02 0.013 0.10 0.38 
rs635634 A G 0.17 0.02 0.004 1.4E-08 0.17 0.19 0.02 0.004 1.9E-07 0.46 0.11 0.03 0.014 0.02 0.07	   
Fasting glucose concentrations were adjusted for sex, age, cohort effects and up to 10 principal components in up to 60,564 (African ancestry 
n=9664 and European ancestry n=50,900) non-diabetic individuals.  Effects are reported per copy of the minor allele.  Beta coefficient units are in 
mmol/L.  EAF: Effect allele frequency. a Conditional p-value; variants near the ABO locus were conditioned on the most significant SNP in the 
region (rs651007).  
	  Supplementary Table 7. Associations of ABO variants genotyped on the HumanExome BeadChip with FG in 
combined European and African ancestries 
	  
Gene rsID Chr Build 37 Position Variation type 
Alleles 
EAF N Beta SE p pconda Proxyb 
Effect Other 
ABO rs7466899 9 136131069 nonsynonymous A G 0.001 59748 0.077 0.047 1.0E-01 0.07 
 ABO rs201604341 9 136131119 nonsynonymous A G 0.000 59748 0.085 0.250 7.3E-01 0.85 
 ABO rs8176749 9 136131188 nonsynonymous T C 0.089 59748 -0.001 0.006 9.2E-01 0.03 Y 
ABO rs8176746 9 136131322 synonymous A C 0.089 59748 0.000 0.006 9.3E-01 0.03 Y 
ABO rs8176745 9 136131347 nonsynonymous A G 0.246 59016 -0.007 0.004 4.4E-02 0.28 
 ABO rs35494115 9 136131389 nonsynonymous A G 0.001 59748 -0.075 0.058 1.9E-01 0.24 
 ABO rs201439325 9 136131407 nonsynonymous A G 0.000 59748 -0.103 0.131 4.3E-01 0.20 
 ABO rs8176741 9 136131461 nonsynonymous A G 0.089 59748 0.000 0.006 1.0E+00 0.02 Y 
ABO rs8176740 9 136131472 nonsynonymous T A 0.246 59748 -0.007 0.004 4.0E-02 0.31 Y 
ABO rs55764262 9 136131539 nonsynonymous G A 0.000 57931 0.056 0.131 6.7E-01 0.92 
 ABO rs55727303 9 136131576 nonsynonymous T C 0.017 57615 -0.003 0.012 7.8E-01 0.68 
 ABO rs7853989 9 136131592 nonsynonymous C G 0.109 49364 0.004 0.006 4.6E-01 0.47 Y 
ABO rs201567722 9 136131629 nonsynonymous T C 0.000 59748 0.034 0.090 7.0E-01 0.91 
 ABO rs55756402 9 136131630 nonsynonymous A G 0.001 59748 0.079 0.057 1.6E-01 0.92 
 ABO rs200932155 9 136131635 nonsynonymous A G 0.001 57615 0.067 0.053 2.0E-01 0.36 
 ABO rs8176738 9 136131636 nonsynonymous T C 0.002 59748 0.003 0.037 9.3E-01 0.31 
 ABO rs1053878 9 136131651 nonsynonymous A G 0.094 59748 -0.005 0.006 4.1E-01 0.34 Y 
ABO rs201105186 9 136131740 nonsynonymous A G 0.000 59748 0.023 0.075 7.6E-01 0.91 
 ABO rs8176721 9 136132852 nonsynonymous A G 0.023 59748 -0.018 0.012 1.4E-01 0.25 
 ABO rs8176720 9 136132873 nonsynonymous C T 0.363 59748 -0.005 0.003 1.1E-01 0.92 Y 
ABO rs512770 9 136133506 nonsynonymous A G 0.217 59748 -0.004 0.004 2.9E-01 0.30 Y 
ABO rs56335272 9 136135236 nonsynonymous T C 0.002 59748 0.057 0.043 1.9E-01 0.14 
 ABO rs549446 9 136135238 nonsynonymous T C 0.257 59748 -0.007 0.004 3.6E-02 0.27 
 ABO rs688976 9 136136770 nonsynonymous A C 0.258 59748 -0.007 0.004 3.6E-02 0.26 
 ABO rs8176696 9 136136773 nonsynonymous T C 0.022 59748 -0.013 0.011 2.3E-01 0.20 
 ABO rs687621 9 136137065 intronic C T 0.348 59748 0.012 0.003 2.0E-04 0.10 
 ABO rs55876802 9 136137547 nonsynonymous A C 0.019 59748 0.013 0.011 2.2E-01 0.38 
 ABO rs55917063 9 136137554 nonsynonymous T C 0.003 59748 -0.081 0.034 1.5E-02 0.02 
 ABO rs657152 9 136139265 intronic T G 0.366 59748 0.012 0.003 2.1E-04 0.39 
 ABO rs514659 9 136142203 intronic C A 0.351 59748 0.010 0.003 1.5E-03 0.39 
 ABO rs505922 9 136149229 intronic C T 0.334 59748 0.011 0.003 1.2E-03 0.39 
 ABO rs507666 9 136149399 intronic A G 0.173 59748 0.022 0.004 7.4E-08 0.28 
 ABO-SURF6 rs651007 9 136153875 intergenic A G 0.196 59502 0.022 0.004 1.3E-08 NA 
 ABO-SURF6 rs579459 9 136154168 intergenic C T 0.196 59502 0.022 0.004 1.6E-08 0.15 
 ABO-SURF6 rs635634 9 136155000 intergenic A G 0.172 59502 0.023 0.004 1.4E-08 0.17   
Fasting glucose concentrations were adjusted for sex, age, cohort effects and up to 10 principal components in up to 60,564 non-diabetic individuals of 
African and European ancestry.  Effects are reported per copy of the minor allele.  Beta coefficient units are in mmol/L.  Bolded p-values meet significance 
threshold for single variant analysis.  EAF: effect allele frequency; N: sample size. a Conditional p-value; variants near the ABO locus were conditioned on 
the most significant SNP in the region (rs651007). b Variant is a proxy for one of the major blood group alleles A1, A2, B or O 
	  Supplementary Table 8. Pleiotropic associations at the ABO locus from 
previously reported studies 
 
rsID Trait Effect          Allele 
Reported effect 
(Beta or OR) Reported p r
2 Reference 
rs651007* sE-selectin T -17.23 1.2E-44 1 1 
rs579459* CAD (OR) C 1.1 4.1E-14 1 2 
rs651007* TC T 2.3 8.7E-21 1 2 
rs579459* TC C 1.72 3.8E-03 1 2 
rs651007 LDL-C A 2.2026 9.8E-09 1 3 
rs579459* LDL-C C 1.54 4.9E-03 1 3 
rs649129 LDL-C T 2.24 6.0E-13 1 4 
rs495828 RBC T -0.091 3.3E-12 1 4 
rs495828 Hb T -0.089 1.2E-11 1 4 
rs495828 Ht T -0.081 6.1E-10 1 4 
rs8176746 MCHC T 0.084 4.3E-08 0.01 5 
rs612169 FAaP G NR 9.1E-40 0.51 6 
rs507666* sICAM-1 A -17.3 3.0E-91 0.96 6 
rs514659 disposition index C -0.09 3.8E-09 0.53 7 
CAD: coronary artery disease, OR: odds ratio, TC: total cholesterol, LDL-C: low-density lipoprotein 
cholesterol, RBC: red blood cell, Hb:hemoglobin concentration, Ht: hematocrit, MCHC: mean 
corpuscular hemoglobin concentration, FAaP: fibrinogen A-alpha phosphorylation, NR: not 
reported, sICAM-1: soluable ICAM1. *Variants associated with fasting glucose in Table 1 and 
Supplementary Table 10.  r2 is between rs651007 and each SNP listed the first column. 
	  Supplementary Table 9. Lookups of ABO top hits in adiposity, lipid, and blood pressure traits 
	  
Adiposity (Nmax=64,965) 
          
rsID Alleles BMI women BMI men WHR women WHR men 
Effect Other Beta SE p Beta SE p Beta SE p Beta SE p 
rs507666 A G 0.021 0.01 4.0E-03 -0.006 0.01 0.53 -0.011 0.01 0.18 0.001 0.01 0.93 
rs651007 A G 0.025 0.01 3.1E-04 -0.004 0.01 0.62 -0.010 0.01 0.23 0.003 0.01 0.77 
rs579459 C T 0.025 0.01 3.5E-04 -0.004 0.01 0.61 -0.010 0.01 0.24 0.003 0.01 0.80 
rs635634 A G 0.020 0.01 6.0E-03 -0.005 0.01 0.60 -0.010 0.01 0.22 0.002 0.01 0.86 
               Lipids (Nmax=56,538) 
          
rsID Alleles HDL-C LDL-C TG TC Effect Other Beta SE p Beta SE p Beta* SE p Beta SE p 
rs507666 A G 0.103 0.11 0.36 2.594 0.30 1.9E-18 -0.001 0.00 0.73 2.748 0.33 5.0E-17 
rs651007 A G 0.052 0.11 0.63 2.276 0.28 6.1E-16 -0.001 0.00 0.88 2.397 0.33 3.4E-13 
rs579459 C T 0.052 0.11 0.63 2.274 0.28 6.5E-16 -0.001 0.00 0.88 2.394 0.33 3.6E-13 
rs635634 A G 0.097 0.11 0.40 2.594 0.30 1.9E-18 -0.002 0.00 0.61 2.681 0.35 1.0E-14 
               Blood pressure (Nmax=92,615) 
         
rsID Alleles DBP SBP       Effect Other Beta SE p Beta SE p 
      rs507666 A G -0.153 0.07 2.5E-02 -0.011 0.11 0.92 
      rs651007 A G -0.096 0.07 0.14 0.016 0.11 0.88 
      rs579459 C T -0.095 0.07 0.15 0.022 0.11 0.84 
      rs635634 A G -0.144 0.07 3.5E-02 0.003 0.11 0.98 
      Fasting lipid concentrations were used. Individuals on lipid or blood pressure lowering medication had their individual values adjusted, see Methods 
for details. Analyses were adjusted for sex (adiposity was stratified by sex), BMI (for WHR), age, cohort effects and up to 10 principal components.  
Effects are reported per copy of the minor allele.  Beta coefficient units are in kg/m2 for BMI,  mg/dL for lipids and mmHg for blood pressure.  BMI: 
body mass index, WHR: waist-hip ratio, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, TG: triglycerides, 
TC: total cholesterol, DBP: diastolic blood pressure, SBP: systolic blood pressure. *Triglycerides are log transformed. 
 
	  Supplementary Table 10. Associations with ABO SNVs and eQTLs from the GTEx 
database 
 
Gene Id Gene Symbol rsID p Tissue 
ENSG00000160326.9 SLC2A6 rs507666 1.1E-04 Whole_Blood 
ENSG00000175164.8 ABO rs651007 5.9E-05 Whole_Blood 
ENSG00000175164.8 ABO rs579459 6.7E-05 Whole_Blood 
ENSG00000160326.9 SLC2A6 rs635634 1.1E-04 Whole_Blood 
	  Supplementary Table 11. Gene based association results for G6PC2 removing 
sets of rare SNVs 
 
cMAF SNVs(n) pSKAT Variant in SKAT gene-based test 
0.014 4 8.3E-18 Y177H, S207Y, R283X, P324S 
0.003 11 0.36 Removing 4 above 
SKAT gene-based test with and without the 4 significant variants identified in 
single variant analyses. Initital gene-based tests (Table 2) used 15 rare SNVs 
(MAF<0.01) and annotated as nonsynonymous, splice-site, or loss/gain-of-
function variants. cMAF: cumulative minor allele frequency; SNVs(n): number 
of SNVs in gene-based SKAT test; pSKAT: p-value from gene-based SKAT 
analysis 
	  Supplementary Table 12. Association of fasting glucose and G6PC2 haplotypes of 
15 rare SNVs 
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C A T A A A T C A T C T A T T 17 -0.22 2.84E-10 
C A T A A A T C A T C T A C C 13 -0.26 1.40E-07 
C A T A A A T C C T C T A C T 18 -0.11 1.45E-06 
C A T A A A T T C T C T A C T 3 -0.89 0.005 
C A T NA A A T T A T C T A T T 1 1.31 0.005 
C A T A A A T T A T C T A C T 16 -0.09 0.021 
T A T A A A T C A T C T A C T 10 -0.22 0.029 
C A T A A G T C A T C T A C T 7 0.22 0.134 
C A T A A A T T A T C T A C T 1 -0.52 0.139 
C C T A A A T C A T C T A C T 3 -0.19 0.140 
C A C A A A T C A T C T A C T 2 0.57 0.216 
C A T A A A T C A T C C A C T 11 -0.13 0.220 
C A T A G A T C A T C T A C T 1 -0.48 0.407 
C A T A NA A T C A C C T A C T 1 0.91 0.417 
C A T A A A C C A T C T A C T 11 -0.07 0.435 
C A T A A A T C C T C T A C C 1 -1.10 0.438 
C A T A A A T T A T C T A C C 1 -0.73 0.592 
T A T A A A T C A T C T A C C 1 0.21 0.645 
C A T T A A T C A T C T A C C 3 -0.21 0.700 
C A T NA A A T C A C C T A C T 1 0.10 0.833 
C A T A A A T C A T C T A C T 18 NA NA 
18 cohorts contributed data. NA is the reference haplotype. Yellow highlighted alleles are the minor 
allele.  N study: number of studies contributing the haplotype observed. 
	  Supplementary Table 13. Association of G6PC2 haplotypes of 15 rare SNVs and 
one common SNV (rs560887) with fasting glucose 
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C A T A A T A T C A T C T A C T 18 -0.08 8.92E-77 
C A T A A T A T C A T C T A T T 17 -0.24 5.63E-12 
C A T A A T A T C C T C T A C T 18 -0.13 7.70E-09 
C A T A A C A T C A T C T A C C 13 -0.28 2.02E-08 
C A T A A T A T T C T C T A C T 3 -0.95 0.003 
C A T NA A T A T T A T C T A T T 1 1.29 0.006 
C A T A A C A T T A T C T A C T 16 -0.11 0.007 
T A T A A C A T C A T C T A C T 10 -0.28 0.010 
C A T A A C A T C A T C C A C T 11 -0.19 0.10 
C A T A A C G T C A T C T A C T 6 0.32 0.17 
C C T A A C A T C A T C T A C T 3 -0.18 0.23 
C A C A A C A T C A T C T A C T 2 0.51 0.26 
C A T A A T A T T A T C T A C T 9 -2.51 0.30 
C A T A G C A T C A T C T A C T 1 -0.53 0.36 
C A T T A C A T C A T C T A C T 1 -0.45 0.37 
C A T A A T A C C A T C T A C T 7 -0.38 0.40 
C A T A A T A T C C T C T A C C 1 -1.13 0.43 
C A T A A C A C C A T C T A C T 9 -0.08 0.43 
C A T A NA C A T C A C C T A C T 1 0.86 0.44 
C A T T A T A T C A T C T A C T 1 -0.96 0.53 
C A T A A C A T T A T C T A C C 1 -0.78 0.57 
C C T A A T A T C A T C T A C T 1 -200 0.57 
C A T A A C A T C C T C T A C T 4 -0.32 0.58 
C A T T A C A T C A T C T A C C 3 -0.25 0.64 
C A T A A T A T C A T C T A C C 8 -0.22 0.66 
T A T A A C A T C A T C T A C C 1 0.16 0.71 
C A T A A T A T C A T C C A C T 4 0.13 0.74 
C A T A A C A T C A T C T A T T 2 -619118 0.76 
C A T A A T G T C A T C T A C T 5 0.06 0.79 
T A T A A T A T C A T C T A C T 6 0.11 0.81 
C A T NA A C A T C A C C T A C T 1 0.05 0.91 
C A T A A C A T C A T C T A C T 18 NA NA 
18 cohorts contributed data. NA is the reference haplotype. Yellow highlighted alleles are the minor allele.  N 
study: number of studies contributing the haplotype observed. 
 
	  Supplementary Table 14. Gene based association results for G6PC2 and fasting 
insulin 
 
Ancestry cMAF SNVs(n) pWST pSKAT N 
Combined ancestry 0.02 17 0.11 0.53 47388 
European ancestry only 0.02 14 0.45 0.55 38528 
African ancestry only 0.01 13 0.75 0.76 8860 
Analyses adjusted for sex, age, cohort effects and up to 10 principal components in 
up to 47,388 in the combined ancestry analysis, 38,528 in the European ancestry 
analysis, and 8860 in the African ancestry analysis. SNVs(n), number of variants 
included in the analysis; variants were restricted to those with MAF<0.01 and 
annotated as nonsynonymous splice-site, or loss/gain-of-function variants. cMAF, 
cumulative MAF: combined minor allele frequency of all variants included in the 
analysis; pWST: p-value from weighted sum test (WST); pSKAT: p-value from 
sequence kernal association test (SKAT); N: sample size. 
	  Supplementary Table 15. Gene based association results for G6PC2 and type 2 
diabetes 
 
Ancestry cMAF SNVs(n) pWST pSKAT N 
Combined ancestry 0.019 18 0.75 0.68 34984 
European ancestry only 0.019 16 0.49 0.52 17651 
African ancestry only 0.010 15 0.60 0.60 3814 
Analyses adjusted for sex, age, cohort effects and up to 10 principal components in 
up to 16,491 T2D cases and 81,877 controls in the combined ancestry analysis, 
10,240 T2D cases and 63,105 controls in the European ancestry analysis, and 3,097 
T2D cases and 10,326 controls in the African ancestry analysis. cMAF, cumulative 
MAF: combined minor allele frequency of all variants included in the analysis. 
SNVs(n), number of variants included in the analysis; variants were restricted to 
those with MAF<0.01 and annotated as nonsynonymous, splice-site, or loss/gain-of-
function variants. pWST: p-value from weighted sum test (WST); pSKAT: p-value 
from sequence kernal association test (SKAT); N: sample size. 
	  Supplementary Table 16. Gene based association results for G6PC2 and fasting 
glucose from exome sequence analyses in up to 7,452 individuals of European 
ancestry 
 
Gene cMAF SNVs(n) pWST pSKAT 
G6PC2 0.027 36 5.4E-04 1.4E-03 
G6PC2  (exome chip variants) 0.018 10 3.2E-03 1.3E-03 
G6PC2  (excluding exome chip variants) 0.009 26 4.0E-02 6.1E-01 
cMAF, cumulative MAF: combined minor allele frequency of all variants included in the 
analysis; SNVs(n): number of variants included in the analysis; pWST: p-value from 
weighted sum test (WST). pSKAT: p-value from sequence kernal association test (SKAT). 
Variants were restricted to those with MAF<0.01 and annotated as nonsynonymous 
splice-site, or loss/gain-of-function variants.SNVs(n)=36 variants met criteria for inclusion 
in gene based tests. SNVs(n)=10 are the same variants available on the exome chip. 
SNVs(n)=26 are the the variants available for analyses after excluding the 10 above. 
	  Supplementary Table 17. Top ten pathways with lowest p-values in MAGENTA 
analysis of FG, analyzing all genes (A) and excluding those with known 
associations with FG (B) 
 
A. 
	   	   	  
Database Pathway name GSEA p-value FDR 
GOTERM Positive regulation of DNA replication 9.80E-05 1.33E-01 
KEGG Glioma 3.00E-04 4.80E-02 
GOTERM Pancreas development 5.00E-04 2.24E-01 
PANTHER Insulin/IGF pathway, protein kinase B signaling cascade 1.00E-03 1.16E-01 
REACTOME Signal attenuation 1.00E-03 1.43E-01 
KEGG Citrate cycle, TCA cycle 1.70E-03 4.63E-02 
INGENUITY IGF-1 signaling 1.80E-03 6.32E-02 
PANTHER DNA repair 1.80E-03 4.61E-01 
KEGG Acute myeloid leukemia 1.90E-03 5.21E-02 
KEGG Type 2 diabetes mellitus 2.20E-03 5.84E-02 
 	   	   	  
B. 
	   	   	  
Database Pathway name GSEA p-value FDR 
KEGG Glioma 1.00E-04 1.59E-02 
GOTERM Positive regulation of DNA replication 1.12E-04 1.68E-01 
KEGG Acute myeloid leukemia 1.50E-03 5.40E-02 
KEGG Focal adhesion kinase 1.60E-03 1.12E-01 
KEGG Non-homologous end joining 2.80E-03 4.50E-02 
KEGG Citrate cycle, TCA cycle 3.00E-03 6.63E-02 
BIOCARTA IGF1 pathway 3.00E-03 3.08E-01 
GOTERM Centrosome organization 3.20E-03 5.03E-01 
GOTERM Oligodendrocyte development 3.70E-03 6.88E-01 
REACTOME Cell cycle, mitotic 3.80E-03 7.37E-01 
	  Supplementary Table 18. Top ten pathways with lowest p-values in MAGENTA 
analysis of FI, analyzing all genes (A) and excluding those with known 
associations with FI (B) 
 
A. 
	   	   	  Database Pathway name GSEA p-value FDR 
GOTERM Response to DNA damage stimulus 9.80E-05 1.33E-01 
REACTOME Regulation of IGF activity by IGF binding proteins 3.00E-04 4.80E-02 
GOTERM ATP binding 5.00E-04 2.23E-01 
GOTERM Solute:hydrogen antiporter activity 1.00E-03 1.16E-01 
REACTOME PECAM1 interactions 1.00E-03 1.44E-01 
GOTERM Dephosphorylation 1.70E-03 4.63E-02 
GOTERM Positive regulation of smooth muscle contraction 1.80E-03 6.32E-02 
BIOCARTA ATRBRCA pathway 1.80E-03 4.61E-01 
GOTERM Rab GTPase binding 1.90E-03 5.21E-02 
GOTERM Nucleotide binding 2.20E-03 5.84E-02 
 	  
	   	  B. 
	  
	   	  Database Pathway name GSEA p-value FDR 
GOTERM Response to DNA damage stimulus 1.00E-04 1.59E-02 
GOTERM ATP binding 1.12E-04 1.68E-02 
REACTOME PECAM1 interactions 1.50E-03 5.40E-02 
GOTERM Protein C-terminus binding 1.60E-03 1.12E-01 
GOTERM Solute:hydrogen antiporter activity 2.80E-03 4.50E-02 
GOTERM Dephosphorylation 3.00E-03 6.63E-01 
GOTERM Positive regulation of smooth muscle contraction 3.00E-03 3.08E-01 
GOTERM Motor activity 3.20E-03 5.03E-01 
GOTERM Rab GTPase binding 3.70E-03 6.88E-01 
GOTERM Cation transport 3.80E-03 7.37E-01 
	  Supplementary Table 19. MAGENTA results for glucometabolic pathways from 
curated pathway databases for FG (A) and FI (B) 
 
A. 	   	   	  
Database Pathway name GSEA p-value FDR 
GOTERM Cellular metabolic process 3.50E-03 6.55E-02 
PANTHER Metabolism of cyclic nucleotides 1.67E-02 4.33E-01 
GOTERM Positive regulation of insulin secretion 1.77E-02 1.36E-01 
REACTOME Glucose and other sugar SLC transporters 2.83E-02 1.10E-01 
KEGG Alpha linoleic acid metabolism 3.88E-02 5.79E-01 
PANTHER Lipid, fatty acid and steroid metabolism 4.17E-02 4.19E-01 
GOTERM 
Hydrolase activity, 
hydrolyzing O-glycosyl 
compounds 
5.24E-02 3.66E-01 
GOTERM Response to glucose stimulus 5.45E-02 2.90E-01 
PANTHER Phospholipid metabolism 5.60E-02 5.65E-01 
REACTOME Metabolism of carbohydrates 5.62E-02 1.00E+00 
 	   	   	  B. 
	   	   	  
Database Pathway name GSEA p-value FDR 
REACTOME 
Regulation of IGF 
activity by IGF binding 
proteins 
8.00E-04 2.30E-03 
GOTERM Xenobiotic metabolic process 6.60E-03 1.49E-01 
GOTERM Regulation of lipid metabolic process 1.59E-02 1.50E-01 
GOTERM Lipid metabolic process 3.73E-02 5.13E-01 
KEGG Inositol phosphate metabolism 5.22E-02 1.00E+00 
GOTERM Response to glucose stimulus 5.48E-02 2.96E-01 
GOTERM Generation of precursor metabolites and energy 6.08E-02 4.87E-01 
GOTERM Response to glucocorticoid stimulus 6.25E-02 2.35E-01 
GOTERM Glucose homeostasis 7.08E-02 1.73E-01 
REACTOME Peroxisomal lipid metabolism 7.21E-02 8.74E-01 
	  Supplementary Table 20. Identifying coding variants significantly associated with fasting glucose and fasting insulin in known 
loci 
	  
Gene Index*/novel rsID Chr Build 37 position 
Alleles Variation type EAF Beta SE p N r2 D' 
Effect Other 
Fasting Glucose              
DNLZ index rs3829109 9 139256766 A G intronic 0.26 -0.01 0.004 1.4E-03 55633 LD with rs3829109 
GPSM1 nsSNV rs60980157 9 139235415 T C nonsynonymous 0.24 -0.02 0.004 2.0E-06 55633 0.62 0.88 
               
SLC30A8 index rs11558471 8 118185733 G A UTR3 0.28 -0.04 0.003 5.5E-24 59748 LD with rs11558471 
SLC30A8 nsSNV rs13266634 8 118184783 T C nonsynonymous 0.27 -0.04 0.004 1.7E-24 59748 0.97 1.00 
               
SLC2A2 index rs11920090 3 170717521 A T intronic 0.17 -0.02 0.004 5.0E-08 59748 LD with rs11920090 
SLC2A2 nsSNV rs5400 3 170732300 A G nonsynonymous 0.18 -0.03 0.004 3.5E-09 59748 1.00 1.00 
               
             LD with rs17762454* 
 "proxy" rs675209 6 7102084 T C intergenic 0.29 0.00 0.003 8.7E-01 59502 0.46 0.71 
RREB1 novel rs35742417 6 7247344 A C nonsynonymous 0.18 -0.02 0.004 6.9E-07 59748 0.04 0.79 
               
MADD index rs7944584 11 47336320 T A intronic 0.24 -0.03 0.004 5.1E-12 59748 LD with rs7944584 
MADD nsSNV rs35233100 11 47306630 T C stopgain 0.05 -0.04 0.007 6.2E-08 59748 0.13 1.00 
ACP2 novel rs2167079 11 47270255 T C nonsynonymous 0.34 0.02 0.003 4.5E-07 59748 0.15 0.93 
AGBL2 novel rs7941404 11 47712213 T C nonsynonymous 0.12 -0.02 0.005 7.0E-06 59748 0.20 0.73 
               
IKBKAP index rs16913693 9 111680359 G T intronic 0.06 -0.02 0.007 1.9E-02 59748 LD with rs16913693 
FAM206A novel rs76817627 9 111696795 T C nonsynonymous 0.02 -0.05 0.010 3.2E-06 59748 1.00 1.00 
IKBKAP novel rs17853166 9 111679940 C T nonsynonymous 0.02 -0.05 0.010 5.7E-06 59748 1.00 1.00 
               
Fasting Insulin              
 index rs10195252 2 165513091 C T intergenic 0.48 -0.02 0.003 2.3E-09 46332 LD with rs10195252 
COBLL1 index rs7607980 2 165551201 C T nonsynonymous 0.13 -0.03 0.004 5.9E-11 47388 0.15 0.83 
Causal gene for MADD and IKBKAP is undetermined since associations are seen in multiple genes and the SNVs r2<.2. Fasting glucose concentrations were 
adjusted for sex, age, cohort effects and up to 10 principal components in up to 60,564 (African ancestry n=9664 and European ancestry n=50,900) non-diabetic 
individuals.  Effects are reported per copy of the minor allele.  Beta coefficient units are in mmol/L. *No proxy for index (rs17762454) is on the exome chip. p-value 
threshold: 1.1x10-5=0.05/4513 SNVs analyzed. EAF: effect allele frequency; N: Sample size, UTR: untranslated region; nsSNV:nonsynonymous single nucleotide 
variant. 
	  Supplementary Table 21. Association of MODY variants with fasting glucose and fasting insulin 
	  
Trait Gene rsID Chr Build 37 Position 
Alleles 
Variation type EAF Beta SE p N 
Effect Other 
FG KLF11 rs34336420 2 10188123 T C nonsynonymous 0.007 -0.013 0.021 0.529 59748 
 
HNF4A rs139591750 20 43047151 G A synonymous 0.002 -0.109 0.036 0.003 59502 
             FI KLF11 rs34336420 2 10188123 T C nonsynonymous 0.008 -0.009 0.019 0.656 47388 
  HNF4A rs139591750 20 43047151 G A synonymous 0.003 -0.062 0.033 0.063 47148 
Fasting glucose concentrations were adjusted for sex, age, cohort effects and up to 10 principal components in up to 60,564 non-
diabetic individuals; beta coefficient units are in mmol/L.  Fasting insulin concentrations were log transformed and adjusted for 
sex, age, BMI, cohort effects and up to 10 principal components in up to 48,118 non-diabetic individuals.  Effects are reported per 
copy of the minor allele.  EAF: effect allele frequency; N: sample size. 
	  
	  Supplementary Table 22. Type of variant on the exome chip by allele frequency 
 
Type All MAF MAF<1% MAF>=1% 
nonsynonymous 128679 32142 96537 
intergenic 8142 8116 26 
intronic 5573 5536 37 
synonymous 3827 1332 2495 
splicing, synonymous 1788 494 1294 
splicing, nonsynonymous 2387 491 1896 
ncRNA intronic 435 434 1 
UTR3 482 431 51 
splicing 1079 307 772 
stopgain 1862 289 1573 
downstream 181 178 3 
upstream 177 176 1 
ncRNA_exonic 101 92 9 
UTR5 69 64 5 
exonic;stoploss 125 33 92 
exonic;splicing 39 15 24 
upstream;downstream 8 8 0 
ncRNA_UTR3 7 7 0 
exonic;splicing;stopgain 31 4 27 
exonic;splicing;stoploss 3 1 2 
ncRNA_splicing 1 1 0 
ncRNA_UTR5 1 1 0 
    TOTAL Disruptive 134205 33282 100923 
TOTAL 154997 50152 104845 
Up to 155,106 SNVs were available for association analyses of 
fasting glucvose and insulin.The type of variant is uncategorized 
for 109 SNVs. MAF: minor allele frequency.  
	  Supplementary Note 1. The EPIC-InterAct Consortium	  
 
Claudia Langenberg(1), Robert A Scott(1), Stephen J Sharp(1), Nita G Forouhi(1), 
Nicola D Kerrison(1), Debora ME Lucarelli (1), Matt Sims(1), Inês Barroso(2,3), Panos 
Deloukas(2), Mark I McCarthy(4,5,6), Larraitz Arriola(7,8,9), Beverley Balkau(10,11), 
Aurelio Barricarte(12,9), Matthias B Schulze (13), Heiner Boeing(13), Paul W 
Franks(14,15), Carlos Gonzalez(16), Sara Grioni(17), Rudolf Kaaks(18), Timothy J 
Key(19), Carmen Navarro(20,9,21), Peter M Nilsson(14), Kim Overvad(22,23), 
Domenico Palli(24), Salvatore Panico(25), J. Ramón Quirós(26), Olov Rolandsson(15), 
Carlotta Sacerdote(27,28), María-­‐José Sánchez(29,9,30), Nadia Slimani(31), Anne 
Tjonneland(32), Rosario Tumino(33,34), Daphne L van der A(35), Yvonne T van der 
Schouw(36), Elio Riboli(37), Nicholas J Wareham(1)  
 
(1) MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom, (2) 
The Wellcome Trust Sanger Institute, Cambridge, United Kingdom, (3) University of 
Cambridge Metabolic Research Laboratories, Cambridge, UK, (4) Oxford Centre for 
Diabetes, Endocrinology and Metabolism (OCDEM), University of Oxford, UK, (5) 
Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK, (6) 
Oxford NIHR Biomedical Research Centre, Oxford, UK, (7) Public Health Division of 
Gipuzkoa, San Sebastian, Spain, (8) Instituto BIO-­‐Donostia, Basque Government, San 
Sebastian, Spain, (9) CIBER Epidemiología y Salud Pública (CIBERESP), Spain, (10) 
Inserm, CESP, U1018, Villejuif, France, (11) Univ Paris-­‐Sud, UMRS 1018, Villejuif, 
France, (12) Navarre Public Health Institute (ISPN), Pamplona, Spain, (13) German 
Institute of Human Nutrition Potsdam-­‐Rehbruecke, Germany, (14) Lund University, 
Malmö, Sweden, (15) Umeå University, Umeå, Sweden, (16) Catalan Institute of 
Oncology (ICO), Barcelona, Spain, (17) Epidemiology and Prevention Unit, Milan, Italy, 
(18) German Cancer Research Centre (DKFZ), Heidelberg, Germany, (19) University of 
Oxford, United Kingdom, (20) Department of Epidemiology, Murcia Regional Health 
Council, Murcia, Spain, (21) Unit of Preventive Medicine and Public Health, School of 
Medicine, University of Murcia, Spain, (22) Department of Public Health, Section for 
Epidemiology, Aarhus University, Aarhus, Denmark, (23) Aalborg University Hospital, 
Aalborg, Denmark, (24) Cancer Research and Prevention Institute (ISPO), Florence, 
Italy, (25) Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, 
Italy, (26) Public Health Directorate, Asturias, Spain, (27) Unit of Cancer Epidemiology, 
Citta' della Salute e della Scienza Hospital-­‐University of Turin and Center for Cancer 
Prevention (CPO), Torino, Italy, (28) Human Genetics Foundation (HuGeF), Torino, 
Italy, (29) Andalusian School of Public Health, Granada, Spain, (30) Instituto de 
Investigación Biosanitaria de Granada (Granada.ibs), Granada (Spain), (31) 
International Agency for Research on Cancer, Lyon, France, (32) Danish Cancer 
Society Research Center, Copenhagen, Denmark, (33) ASP Ragusa, Italy, (34) Aire 
Onlus, Ragusa, Italy, (35) National Institute for Public Health and the Environment 
(RIVM), Bilthoven, The Netherlands, (36) University Medical Center Utrecht, Utrecht, 
the Netherlands, (37) School of Public Health, Imperial College London, UK  
	  
 
 
	  SUPPLEMENTARY NOTE 2. CHARGE T2D-Glycemia Exome Consortium Study 
Descriptions 
 
Age, Gene/Environment, Susceptibility—Reykjavik (AGES) Study  
The AGES study has been described previously. The study was initiated in 2002 to 
examine genetic susceptibility and gene/environment interactions related to disease and 
disability in old age. The AGES study is comprised of 5,764 individuals drawn from the 
Reykjavik Study, a population-based cohort comprised of individuals born between 
1907 and 1935 and followed since 1967 by the Icelandic Heart Association. 2983 
individuals have ExomeChip genotypes1. 
 
Atherosclerosis Risk in Communities (ARIC) Study 
The ARIC Study is a prospective cohort study of cardiovascular disease risk in four US 
communities2. Between 1987 and 1989, 7,082 men and 8,710 women aged 45–64 
years were recruited from Forsyth County, North Carolina; Jackson, Mississippi (African 
Americans only); suburban Minneapolis, Minnesota; and Washington County, Maryland. 
The ARIC Study protocol was approved by the institutional review board of each 
participating university. After written informed consent was obtained, including that for 
genetic studies, participants underwent a baseline clinical examination (Visit 1) and four 
subsequent follow-up exams (Visits 2 – 5). 
 
Coronary Artery Risk Development in young Adults (CARDIA) 
The CARDIA study is a prospective, multi-center investigation of the natural history and 
etiology of cardiovascular disease in African Americans and whites 18-30 years of age 
at the time of initial examination. The initial examination included 5,115 participants 
selectively recruited to represent proportionate racial, gender, age, and education 
groups from four communities: Birmingham, AL; Chicago, IL; Minneapolis, MN; and 
Oakland, CA. Participants from the Birmingham, Chicago, and Minneapolis centers 
were recruited from the total community or from selected census tracts. Participants 
from the Oakland center were randomly recruited from the Kaiser-Permanente health 
plan membership. From the time of initiation of the study in 1985-1986, seven follow-up 
examinations have been conducted at years 2, 5, 7, 10, 15, 20, and 25. 
 
The Chinese American Eye Study (CHES) is a population-based study designed to 
assess the prevalence and risk factors of visual impairment, diabetic retinopathy, age-
related macular degeneration, lens opacities, glaucoma and myopia, and to determine 
potential unique genetic associations with ocular disease in 4,582 (79% participation) 
non-institutionalized Chinese Americans aged 50 years and older living in Monterey 
Park, in Los Angeles County. Household residence were determined eligible if they lived 
in Monterey Park, were 50 years or older, and self-reported Chinese Americans. Eligible 
participants were asked to complete an in-home questionnaire which included 
demographic and ocular history information. Participants were then invited to complete 
a comprehensive eye examination, including presenting and best-corrected visual acuity 
measurements, visual field, intraocular pressure, random glucose, Hba1c, lens grading, 
fundus photography and diabetes status.  
 
	  Cardiovascular Health Study (CHS) 
CHS is an NHLBI-funded observational study of risk factors for cardiovascular disease 
in adults 65 years or older3. Starting in 1989, and continuing through 1999, participants 
underwent annual extensive clinical examinations. Measurements included traditional 
risk factors such as blood pressure and lipids as well as measures of subclinical 
disease, including echocardiography of the heart, carotid ultrasound, and cranial 
magnetic-resonance imaging (MRI). At six month intervals between clinic visits, and 
once clinic visits ended, participants were contacted by phone to ascertain 
hospitalizations and health status. The main outcomes are coronary heart disease 
(CHD), angina, heart failure (HF), stroke, transient ischemic attack (TIA), claudication, 
and mortality. Participants continue to be followed for these events.  Participants of 
either European or African-American Ancestry were included in this study and signed 
informed test for genetic testing. 
 
CoLaus Study 
The CoLaus study is a community-based study of 6188 European white subjects aged 
35 ~75 years4. Participants were drawn from the CHUV University Hospital in Lausanne 
Switzerland and studied for cardiovascular and metabolic phenotypes.   
 
CROATIA-Korcula (Korcula) Study 
The CROATIA-Korcula study includes 969 Croatians between the ages of 18 and 98. 
The field work was performed in 2007 and 2008 in the eastern part of the island, 
targeting healthy volunteers from the town of Korcula and the villages of Lumbarda, 
Zrnovo and Racisce.  Ethical approval was obtained from appropriate regulatory bodies 
in both Scotland and Croatia and participants gave informed consent prior to joining the 
study. After all quality control measures, 855 European individuals were successfully 
genotyped using the Illumina HumanExome BeadChip array5. 
 
European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam 
Study 
The European Prospective Investigation into Cancer and Nutrition (EPIC) – Potsdam 
recruited men aged 40 to 64 years and women aged 35 to 64 years from the general 
population in Potsdam and surrounding municipalities from 1994 – 19986 and is part of 
the multi-center prospective cohort study EPIC7. The baseline assessment included a 
blood collection, self-administered questionnaires for assessment of lifestyle, socio-
demographic factors and dietary habits, a personal interview on lifestyle habits and 
medical history as well as a physical examination to measure among others 
anthropometric characteristics8. A total number of 27,548 individuals participated in the 
study. From all participants that provided blood samples (n=26,444), a subcohort 
sample of 2,500 individuals was drawn randomly for measurement of genetic and bio-
markers. Genotyping was additionally performed in 795 incident type 2 diabetes cases. 
Incident type 2 diabetes cases (N=849, mean follow-up time =7 years) were identified 
by an active follow up procedure9. Self-reports of diabetes diagnosis, diabetes-relevant 
medication, or dietary treatment due to diabetes were verified by questionnaires mailed 
to the diagnosing physician. Only subjects with a verified type 2 diabetes diagnosis 
were included in the analysis. The EPIC-Potsdam study was approved by the Ethics 
	  Committee of the Medical Association of the State of Brandenburg (Germany). All 
participants provided written, informed consent at study entry. 
 
The Exeter Family Study of Childhood Health (EFSOCH) 
The EFSOCH is a prospective study, set up to test the fetal insulin hypothesis, and to 
identify genetic polymorphisms that play a role in determining birthweight and early 
postnatal growth. We recruited 1,017 families from a postcode-defined area in central 
Exeter. Specific inclusion criteria were established to obtain a homogeneous, non-
diabetic, UK Caucasian cohort. Detailed anthropometric measurements were taken from 
both parents at 28 weeks’ gestation, and from their children at birth, 12 weeks, 1 year 
and 2 years of age. Insulin and other biochemical analysis were measured in fasting 
parental samples and an umbilical cord blood sample taken at delivery. Parental and 
offspring DNA were extracted to allow molecular genetic analysis of candidate genes 
implicated in fetal growth10. 
 
The Erasmus Rucphen Family (ERF) Study  
The ERF Study is a family-based cohort study in a genetically isolated population in the 
southwest of the Netherlands. Approximately 3,200 individuals, spanning an age range 
from 18 to 86 years old, participated in the study. The cross-sectional examinations took 
place between 2002 and 2005. The rationale and study design have been described 
elsewhere11,12. 
 
Family Heart Study (FamHS) 
The FamHS began in 1992 with the ascertainment of 1,200 European American 
families, half randomly sampled, and half selected because of an excess of coronary 
heart disease or risk factor abnormalities as compared with age- and sex-specific 
population rates13. The families, with approximately 6,000 individuals, were sampled on 
the basis of information on probands from four population-based parent studies: the 
Framingham Heart Study (Boston, MA), the Utah Family Tree Study (Salt Lake City, 
UT), and two Atherosclerosis Risk in Communities (ARIC) study centers (Minneapolis, 
MN, and Forsyth County, NC). Eight years later, study participants belonging to the 
largest pedigrees were invited for a second clinical exam (2002-04).  Approximately 
82% of the recruited subjects returned for the second visit and 275 newly eligible family 
members were also recruited. In addition, a sample of 633 family members including 
153 T2D subjects from 215 African American families was recruited at an additional 
ARIC field center (Birmingham, AL).  
 
FENLAND Study 
The Fenland Study is an ongoing, population-based cohort study (started in 2005) 
designed to investigate the association between genetic and lifestyle environmental 
factors and the risk of obesity, insulin sensitivity, hyperglycemia and related metabolic 
traits in men and women aged 30 to 55 years. Potential volunteers were recruited from 
General Practice sampling frames in the Fenland, Ely and Cambridge areas of the 
Cambridgeshire Primary Care Trust in the UK. Exclusion criteria for the study were: 
prevalent diabetes, pregnant and lactating women, inability to participate due to terminal 
illness, psychotic illness, or inability to walk unaided. All participants had measurements 
	  done at the MRC Epidemiology Unit Clinical Research Facilities in Ely, Wisbech and 
Cambridge. Participants attended after an overnight fast for a detailed clinical 
examination, and blood samples were collected. The Local Research Ethics Committee 
granted ethical approval for the study and all participants gave written informed consent. 
 
Framingham Heart Study (FHS)  
The FHS is a three generational prospective cohort that has been described in detail 
previously14. Individuals were initially recruited in 1948 in Framingham, USA to evaluate 
cardiovascular disease risk factors. The second generation cohort (5,124 offspring of 
the original cohort and their spouse) was recruited between 1971 and 1975. The third 
generation cohort (4,095 grandchildren of the original cohort) was collected between 
2002 and 2005. 8,153 European-American individuals had good quality genotypes from 
the Illumina HumanExome BeadChip array. 
 
First Myocardial Infarction in Northern Sweden 3 (FIA3) Study 
FIA3 is a population-based study of myocardial infarction (MI) nested within the 
Northern Sweden Health and Disease Study, (NSHDS), a population-based cohort 
study from northern Sweden, which consists of sub cohorts: the Västerbotten 
Intervention Program (VIP) and the WHO’s Multinational Monitoring of Trends and 
Determinants in Cardiovascular Disease (MONICA) Study in northern Sweden. Both 
VIP and MONICA are health examination programs for cardiovascular disease (CVD) 
and diabetes. Cases are identified through the MONICA study in northern Sweden and 
its MI incidence registry. For the current study 2657 cases were genotyped with Illumina 
HumanExome BeadChip 12 v1.115. 
 
Gene-Lifestyle interactions And Complex traits Involved in Elevated disease Risk 
(GLACIER) Study 
The Gene-Lifestyle interactions And Complex traits Involved in Elevated disease Risk 
(GLACIER) Study is nested within the Västerbotten Health Survey, which is part of the 
Northern Sweden Health and Disease Study, a population-based prospective cohort 
study from northern Sweden. A total of 1000 non-diabetic participants from the 
GLACIER Study were genotyped with Illumina HumanExome Beadchip 12 v1.115. 
 
Generation Scotland: Scottish Family Health Study (GS:SFHS) 
The Generation Scotland: Scottish Family Health Study is a collaboration between the 
Scottish Universities and the NHS, funded by the Chief Scientist Office of the Scottish 
Government. GS:SFHS is a family-based genetic epidemiology cohort with DNA, other 
biological samples (serum, urine and cryopreserved whole blood) and socio-
demographic and clinical data from ~24,000 volunteers, aged 18-98 years, in ~7,000 
family groups. Participants were recruited across Scotland, with some family members 
from further afield, from 2006 - 2011. Most (87%) participants were born in Scotland and 
96% in the UK or Ireland. The cohort profile has been published. GS:SFHS operates 
under appropriate ethical approvals, and all participants gave written informed consent. 
After all quality control procedures had been carried out, 9955 participants of European 
ancestry were genotyped using the Illumina HumanExome BeadChip array16. 
 
	  The Johns Hopkins Genetic Study of Atherosclerosis Risk (GeneSTAR)   
GeneSTAR is a longitudinal family-based study examining determinants of incident 
coronary artery disease, stroke, and vascular disease among apparently healthy first 
degree adult relatives of probands who were hospitalized in Baltimore, Maryland, with 
documented coronary disease prior to 60 years of age. African American and white 
family members who were 21-80 years of age were enrolled between 1983 and 2007, 
and have been followed at regular five-year intervals. 
 
GoMAP (Genetic Overlap between Metabolic and Psychiatric traits) 
The GOMAP study includes 2871 unrelated Greek nationals of European ancestry 18-
98 years of age recruited from five different hospitals in Athens Greece between 2012 
and 2014. The study aims to explore shared inherited risk factors for metabolic and 
psychiatric disease. Genome-wide association scan (GWAS) was applied to biological 
samples from 422 individuals with type 2 diabetes (T2D). Clinical and 
haematological/biochemical measurements, interview-based lifestyle and socio-
demographic information, detailed anthropometric measurements as well as information 
on treatment of T2D volunteers were collected. The cohort included in the present work 
comprises candidates with T2D regularly followed up in the outpatient diabetes centers 
(more than three outpatient visits on separate days) and receiving a prescriptions for 
insulin or oral antidiabetic agents. For newly diagnosed T2D patients ascertainment was 
conducted according to the WHO criteria. Ethical permission was obtained from the 
appropriate regulatory bodies and all volunteers gave written informed consent. 
 
Health, Aging, and Body Composition (Health ABC) Study 
Health ABC is a longitudinal, prospective study that tracks functional limitation onset 
and progression in a cohort of high-functioning older men and women recruited from 
Memphis, TN and Pittsburgh, PA using Medicare records.  Recruitment began in 1997-
1998 when participants were between 70 and 79 years of age and entry into study was 
dependent on participants' ability to walk one-quarter mile and climb 10 steps without 
difficulty. At baseline, the Health ABC cohort included 3,075 men and women, including 
552 African-American men and 729 African-American women.  The goal of the study is 
to understand how change in body composition and weight-related health conditions 
contributed to and affected incident functional limitation.  Clinic examinations were 
conducted at baseline and at years 2, 3, 4, 5, 6, 8, 10, 11, and 16.  Follow-up interviews 
by telephone have been conducted every six months since study initiation. 
 
Health2008 
Health2008 is a population-based epidemiological study of general health, diabetes and 
cardiovascular disease comprising 771 participants. An oral glucose tolerance test was 
performed with measurement of plasma glucose and serum insulin at fasting and 30 
and 120 min after glucose intake. Health2008 was conducted at the Research Centre 
for Prevention and Health in Glostrup, Denmark. Informed written consent was obtained 
from all study participants. The studies were conducted in accordance with the 
Declaration of Helsinki II and were approved by the local Ethical Committee. 
 
Hellenic Isolated Cohorts (HELIC) Study 
	  The HELIC (Hellenic Isolated Cohorts) MANOLIS (Minoan Isolates) and Pomak 
collections focus on the Cretan Mylopotamos villages and the Pomak villages in 
Greece, respectively. Recruitment of these population-based samples was primarily 
carried out at the village medical centres. The study includes biological sample 
collection for DNA extraction and lab-based blood measurements, and interview-based 
questionnaire filling. The phenotypes collected include anthropometric and biometric 
measurements, clinical evaluation data, biochemical and haematological profiles, self-
reported medical history, demographic, socioeconomic and lifestyle information. 
Biochemical measurements were obtained using enzymatic colorimetric assays and 
included glucose (hexokinase method, insulin and ferritin were measured via 
chemiluminescence and C-reaction protein (CRP) through an immunoturbidimetric 
method. The study was approved by the appropriate institutional review board (IRB) and 
appropriate informed consent was obtained from human subjects. 
 
INCIPE Study 
The INCIPE study (Initiative on Nephropathy, of relevance to public health, which is 
Chronic, possibly in its Initial stages, and carries a Potential risk of major clinical End-
points) aims to explore the prevalence of CKD and related cardiometabolic traits in 
Italy17. Six thousand and two hundred (6,200) individuals, all Caucasians, ≥40-years old 
by January 1, 2006, were randomly chosen from the lists of patients of 62 randomly 
selected general practitioners (GPs) based in four geographical areas in the Veneto 
region, NE Italy. After exclusion of pregnant or lactating women, a written informed 
consent was obtained from a total of 3,870 subjects (62%). Each participant filled a self-
administered questionnaire on family and personal medical history, pharmacologic 
treatments, smoking habits etc. Participants attended after an overnight fast for a 
detailed clinical examination performed locally in four units by trained medical doctors 
and blood and urine samples were collected with a standardized protocol. All 
determinations were centralized (Hospital Trust of Verona, Central Laboratory, Verona, 
Italy). Patients were asked to refrain from smoking beginning from the night before. BP, 
waist circumference, body weight, and height were measured as in the NHANES 
study18. About 2,500 study participants underwent Illumina ExomeChip v.1.0 
genotyping, 1,933 of them (1,749 non-T2D, 184 affected by T2D) had complete 
information to contribute to the present study. 
 
Inter99 
The Inter99 cohort is a randomized, non-pharmacological intervention study for the 
prevention of ischaemic heart disease, conducted on 6,784 randomly ascertained 
participants aged 30 to 60 years at the Research Centre for Prevention and Health in 
Glostrup, Denmark (ClinicalTrials.gov: NCT00289237). An oral glucose tolerance test 
was performed with measurement of plasma glucose and serum insulin at fasting and 
30 and 120 min after glucose intake. Subsequently, 6,094 participants of Danish 
nationality and with available DNA were classified as having normal glucose tolerance 
(n=4,525), impaired fasting glycaemia (n=504), impaired glucose tolerance (n=693), 
screen-detected type 2 diabetes (n=253), or previously diagnosed type 2 diabetes 
(n=119) according to World Health Organization (WHO) 1999 criteria. Informed written 
consent was obtained from all study participants. The studies were conducted in 
	  accordance with the Declaration of Helsinki II and were approved by the local Ethical 
Committee. 
 
InterAct Consortium 
The InterAct study19 is a case-cohort study nested within the European Prospective 
Investigation into Cancer and Nutrition (EPIC) cohorts7, and includes 12,403 incident 
cases of T2D and a subcohort of 16,154 individuals (including 778 randomly selected 
incident T2D cases). Up to 2,266 incident cases of T2D and 3,734 controls genotyped 
on the Illumina CoreExome chip were included in the current analysis.   
 
IPM BioMe Biobank  
The BioMe Biobank Program is an ongoing, prospective, hospital- and outpatient- 
based population research program operated by The Charles Bronfman Institute for 
Personalized Medicine (IPM) at Mount Sinai. BioMe has enrolled over 26,500 
participants between September 2007 and August 2013. BioMe is an Electronic Medical 
Record (EMR)-linked biobank that integrates research data and clinical care information 
for consented patients at The Mount Sinai Medical Center, which serves diverse local 
communities of upper Manhattan with broad health disparities. IPM BioMe populations 
include 25% of African American ancestry (AA), 36% of Hispanic Latino ancestry (HL), 
30% of white European ancestry (EA), and 9% of other ancestry. The IPM BioMe 
disease burden is reflective of health disparities in the local communities. BioMe 
operations are fully integrated in clinical care processes, including direct recruitment 
from clinical sites waiting areas and phlebotomy stations by dedicated BioMe recruiters 
independent of clinical care providers, prior to or following a clinician standard of care 
visit. Recruitment currently occurs at a broad spectrum of over 30 clinical care sites. 
Analyses of BioMe data was supported in part through the computational resources and 
staff expertise provided by the Department of Scientific Computing at the Icahn School 
of Medicine at Mount Sinai. 
 
Insulin Resistance Atherosclerosis Study (IRAS) 
IRAS was an epidemiologic cohort study designed to examine the relationship between 
insulin resistance and carotid atherosclerosis across a range of glucose tolerance. 
Individuals of self-reported African-American ethnicity were recruited in Oakland, CA 
and Los Angeles, CA. Recruitment was balanced across age and glucose tolerance 
status. The overall cohort consisted of 464 African-American individuals. 
 
The Insulin Resistance Atherosclerosis Study Family Study (IRASFS) 
IRASFS was a family study designed to examine the genetic and epidemiologic basis of 
glucose homeostasis traits and abdominal adiposity. Self-reported Mexican-American 
pedigrees were recruited in San Antonio, TX and San Luis Valley, CO. Probands with 
large families were recruited from the initial non-family-based IRAS Study. The overall 
cohort consisted of 1,414 Mexican-American individuals from 90 families and 596 
African-American individuals from 42 families. 
 
Jackson Heart Study (JHS) Study Description 
	  The Jackson Heart Study is a community-based observational study of African 
Americans in the Jackson, MS, metropolitan area. Beginning in 2000 5,301 participants 
(mean age 54.9 ± 12.9) were enrolled to explore the causes of the large burden of 
common complex diseases in this population. Participants have been evaluated during 
three clinic examinations (2000-2004, 2004-2008, and 2009-2012). ExomeChip 
genotyping has been performed for 2,790 participants20. 
 
LOLIPOP Study 
A population-based study of 21,915 subjects, primarily of Indian Asians and 
Northwestern Europeans aged 35–75 years, identified from the lists of 58 general 
practitioners in West London21. 549 European whites with exome sequencing data 
available from the GSK discovery sequence project were included in the current study. 
 
Metabolic Syndrome GEMS Study 
The GEMS study is a large multinational study designed to explore the genetic basis of 
the metabolic syndrome control22. Subjects were recruited from two centers in Europe 
(Oulu, Finland and Lausanne, Switzerland), one in the United States (Dallas, TX), one 
in Canada (Ottawa, Ontario), and one in Australia (Adelaide, South Australia).  
Dyslipidemic subjects were required to have the combination of an elevated plasma 
triglyceride (greater than 75th percentile) and a low serum HDL-cholesterol (less than 
25th percentile) for their age, sex and country threshold (age 18-75 years) and were 
non-diabetic. Unrelated normolipidemic controls were required to have plasma 
triglyceride lower than 50th percentile, serum HDL-cholesterol greater than 50th 
percentile for their age, sex and country threshold, body mass index (BMI) greater than 
25 kg/m2, and be greater than 40 years of age.  Dyslipidemic subjects (n=787 subjects) 
and normolipidemic controls (n=792 subjects), matched by sex, age and collection 
center were sequenced in the GSK discovery sequence project and included in the 
current study.   
 
METSIM (METabolic Syndrome In Men) Study 
The METSIM Study includes 10,197 men, aged from 45 to 73 years at recruitment, 
randomly selected from the population register of the Kuopio town, Eastern Finland, and 
examined in 2005-201023. Study protocol included interview on cardiovascular risk 
factors, measurement of height, weight, waist, hip, blood pressure, and bioimpedance 
for the evaluation of fat percentage. Laboratory studies include an oral glucose 
tolerance test to evaluate glucose tolerance (samples for glucose and insulin at 0, 30, 
and 120 minutes), as well as fasting laboratory measurements including lipids, 
lipoproteins, inflammatory markers, etc.  
 
MRC Ely  
The MRC Ely Study is a population-based cohort randomly selected from people living 
in Ely and surrounding villages (East Anglia, UK), an ethnically homogenous European 
ancestry population. The study design, methods and measurements of the three phases 
have been described in detail elsewhere. The current analyses included individuals 
aged 35-79 years, from phase 3. Ethical permission was granted by the Cambridgeshire 
	  Research Ethics Committee, and study participants provided written informed consent. 
Data from 1394 individuals were included in the current analyses.  
 
Multi-Ethnic Study of Atherosclerosis (MESA) Study 
Three components of the Multi-Ethnic Study of Atherosclerosis (MESA, MESA Family, 
and MESA Air) underwent genotyping with the Exome chip as part of the MESA SNP 
Health Association Resource (SHARe). The parent MESA study is a National Heart, 
Lung and Blood Institute-sponsored, population-based investigation of subclinical 
cardiovascular disease and its progression24. In brief, a total of 6,814 individuals, aged 
45 to 84 years, were recruited from six US communities (Baltimore City and County, 
MD; Chicago, IL; Forsyth County, NC; Los Angeles County, CA; New York, NY; and St. 
Paul, MN) between July 2000 and August 2002. Thirty-eight percent of the recruited 
participants are white, 28 percent African-American, 22 percent Hispanic, and 12 
percent Asian (predominantly of Chinese descent). In MESA Family, 2,128 additional 
individuals from 594 African-American and Hispanic-American families were recruited 
utilizing the existing MESA framework. MESA Air, a study of air pollution exposure and 
cardiovascular disease, primarily consists of participants from MESA and MESA Family, 
plus 257 subjects recruited specifically for MESA Air from Los Angeles and New York. 
For the current study, there were 2456 white and 1549 African-American individuals 
with fasting glucose or fasting insulin and Exome chip data available for analysis. 
 
Precocious Coronary Artery Disease (PROCARDIS) Study 
The PROCARDIS (Precocious Coronary Artery Disease) Study recruited subjects with 
coronary artery disease at/before 65 years. Control subjects free of CAD before 65 
years, were recruited from the same centers as cases. Ethics approval was granted by 
the each recruitment center (Sweden, UK, Germany, Italy). All participants completed a 
questionnaire including baseline characteristics, lifestyle, cardiovascular risk factors and 
medication. Standard biochemical phenotyping was performed25. 
 
Relationship between Insulin Sensitivity and Cardiovascular disease (RISC) Study 
The RISC (Relationship between Insulin Sensitivity and Cardiovascular disease) Study 
is being carried out in 19 European recruiting centers to examine whether insulin 
sensitivity (directly measured with the euglycemic clamp technique) predicts 
cardiovascular disease (CVD) independently of other factors. The study makes use of 
ultrasound scans of the carotid artery and takes the thickness of the intima-media layer 
in the artery wall (IMT) as an early marker of atherosclerosis26. 
 
Rotterdam Study 
The Rotterdam Study is an ongoing prospective population-based cohort study, focused 
on chronic disabling conditions of the elderly. The study comprises an outbred ethnically 
homogenous population of Dutch Caucasian origin. The rationale of the study has been 
described in detail elsewhere27. In summary, 7,983 men and women aged 55 years or 
older, living in Ommoord, a suburb of Rotterdam, the Netherlands, were invited to 
participate. A total of 2986 individuals from the initial study were included in the current 
study27,28. 
 
	  Stockholm Coronary Artery Risk Factor (SCARF) Study 
Subjects <60 years admitted to 3 coronary care units in Stockholm (Danderyd Hospital, 
Karolinska Hospital and Norrtälje Hospital) for first MI were included in this study 
(n=387). Healthy age, county and sex-matched control were also recruited for each 
case. Blood sampling was carried out 3 months after the cardiac event at a medical 
examination under fasting conditions. In addition, an interview of social-economic 
factors, lifestyle and medical history was completed. Ethics approval was granted by the 
ethics committee at Karolinska29. 
 
Singapore Chinese Eye (SCES) Study 
SCES is a population-based cross-sectional study of eye diseases in Chinese adults 40 
years of age or older residing in the south-western part of Singapore. The study was 
designed to ascertain the prevalence and impact of major eye disease in Chinese 
persons in Singapore. An age-stratified (by 10-year age group) random sampling 
strategy was used to select participants from a computer-generated list provided by the 
Ministry of Home Affairs, Singapore. Between 2009 and 2011, 3,353 (72.8%) of 4,605 
eligible individuals underwent a comprehensive physical and ophthalmologic 
examinations. Of these 2492 had ExomeChip data. The study adhered to the tenets of 
the Declaration of Helsinki, and ethical approval was obtained from the Institutional 
Review Board of the Singapore Eye Research Institute. All participants provided written 
informed consent. 
 
Taiwan US Diabetic Retinopathy (TUDR) Study  
Taiwan US Diabetic Retinopathy (TUDR) is a cohort that enrolled subjects with Type 2 
diabetes receiving care at Taichung Veteran General Hospital (Taichung VGH), and a 
small number of subjects from Taipei Tri-Service General Hospital. All TUDR subjects 
underwent a complete ophthalmic and fundus examination to carefully document the 
presence and extent of retinopathy. 
 
TEENAGE (TEENs of Attica: Genes and Environment) 
The TEENAGE study comprises 857 adolescents of Greek origin randomly recruited 
from public secondary schools located in the wider Athens area of Attica in Greece30.  
 
ULSAM  
All men born between 1920 and 1924 in Uppsala, Sweden were invited to participate at 
age 50 in this longitudinal cohort study that was started in 1970. Participants were 
reinvestigated at the ages of 60, 70, 77, 82 and 88 years.1 Blood samples for DNA 
extraction and main cardiovascular risk factors were available from the investigation at 
age 70 (n=1,146 with DNA and data on CVD risk factors). The participants have 
undergone extensive phenotyping at repeated time points, including euglycemic clamps, 
oral glucose tolerance tests, DXA, echocardiography, 24-h ambulatory blood pressure 
measurement, and a range of biomarkers. 
 
Val Borbera (INGI-VB) Study 
The INGI-­‐Val Borbera population is a collection of 1803 samples recruited in the Val 
Borbera Valley, a geographically isolated valley located within the Appennine Mountains 
	  in Northwest Italy 31,32. The valley is inhabited by about 3,000 descendants from the 
original population, living in 7 villages along the valley and in the mountains. 
Participants were healthy people 18-102 years of age, 54% females having at least one 
grandfather living in the valley.  Initial recruitment was in 2005-2008.  
 
WGHS 
The Women’s Genome Health Study (WGHS, n=23,294) is a prospective cohort of 
initially healthy, female North American health care professionals at least 45 years old 
at baseline representing a subset of participants in the Women’s Health Study (WHS) 
who provided a blood sample at baseline and consent for blood-based analyses. The 
WHS was a 2x2 trial beginning in 1992-1994 of vitamin E and low dose aspirin in 
prevention of cancer and cardiovascular disease with about 10 years of follow-up.  
Since the end of the trial, follow-up has continued in observational mode. Additional 
information related to health and lifestyle were collected by questionnaire throughout the 
WHS trial and continuing observational follow-up33. 
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